Addressing Community Oncologists’ Questions About Antibody-Drug Conjugates and Bispecific Antibodies for Multiple Myeloma — What Clinicians Want To Know

Join us on Friday, December 11^th from 7:00 PM to 9:00 PM central time (8:00 PM to 10:00 PM eastern time).

Module 1: Current Utility of Antibody-Drug Conjugates (ADCs) for Multiple Myeloma (MM)

• Mechanism of action and structural components of belantamab mafodotin
• Extended follow-up from the Phase III DREAMM-7 and DREAMM-8 trials evaluating belantamab mafodotin-containing regimens for patients with relapsed/refractory (R/R) MM
• FDA approval and current role of belantamab mafodotin/bortezomib/dexamethasone in the management of R/R MM
• Final analysis of the Phase I DREAMM-9 study and ongoing evaluation of belantamab mafodotin-containing combinations for newly diagnosed MM
• Other novel BCMA- and non-BCMA-targeted ADCs under investigation for MM

Module 2: Ocular Toxicities and Other Tolerability Considerations with ADCs for MM

• Pathogenesis and incidence of ocular adverse reactions associated with belantamab mafodotin
• Recommended approaches to monitoring for, preventing and managing ocular adverse events
• Spectrum and management of other side effects, such as cytopenias, hepatotoxicity, diarrhea and fatigue, in patients receiving belantamab mafodotin

Module 3: Integrating BCMA-Targeted Bispecific Antibodies into the Management of MM: Efficacy, Safety and Adverse-Event Management

• Pharmacologic similarities and differences among approved and investigational BCMA x CD3 bispecific antibodies for MM
• Available efficacy and safety findings leading to the FDA approvals of teclistamab, elranatamab and linvoseltamab
• FDA approval of teclistamab in combination with daratumumab for patients with R/R MM
• Selection of appropriate candidates for BCMA-directed bispecific antibody therapy and optimal incorporation of this approach in the context of other available treatment options
• Early data with and ongoing assessment of BCMA-targeted bispecific antibody-containing combination strategies and/or earlier uses of these agents, including in the front-line setting
• Incidence, severity, time course and common signs and symptoms of cytokine release syndrome with available and investigational bispecific antibodies; approaches for mitigation and management
• Spectrum, frequency and management of other adverse events, including neurotoxicity and cytopenias and infections, with bispecific antibodies

Module 4: Current and Future Role of Bispecific Antibodies with Other Targets in MM: Efficacy, Safety and Adverse-Event Management

• Biological rationale for the development of bispecific antibodies with targets beyond BCMA in MM, such as GPRC5D and FcRH5
• Long-term efficacy and safety reported with the GPRC5D-targeted bispecific antibody talquetamab in the pivotal Phase I/II MonumenTAL-1 study
• Available (MonumenTAL-3) and emerging (MonumenTAL-6) Phase III datasets with talquetamab in combination with other systemic therapies
• Preliminary findings with the FcRH5-directed bispecific antibody cevostamab as monotherapy and in combination for R/R MM
• Design, eligibility criteria and primary and secondary endpoints of the Phase III CEVOLUTION trial of cevostamab in combination with pomalidomide and dexamethasone for patients with MM who have received 1 to 3 prior lines of therapy
• Tolerability profiles of talquetamab and cevostamab; similarities and differences between these agents and BCMA-targeted bispecific antibodies

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of multiple myeloma (MM).

Learning Objectives
At the conclusion of this activity, participants should be able to

• Assess available clinical research findings with BCMA-directed antibody-drug conjugates (ADCs) for relapsed/refractory (R/R) MM to facilitate their integration into management algorithms.
• Develop strategies to identify patients appropriate for treatment with BCMA-directed ADC therapy, and counsel them regarding the risks and benefits.
• Assess available and emerging research data with BCMA-directed bispecific antibodies alone and in combination with other systemic therapies for patients with R/R MM, and appreciate the clinical role of these agents.
• Review the biological rationale for and published and emerging research findings with bispecific antibodies targeting G protein-coupled receptor class C group 5 member D (GPRC5D), administered alone and in combination with other systemic therapies for MM, and evaluate how best to sequence FDA-approved agents.
• Appreciate the scientific justification for the development of Fc receptor-homolog 5 (FcRH5)-targeted bispecific antibodies, and appraise ongoing research efforts attempting to definitively established the efficacy and safety of these agents.
• Implement a plan of care to recognize and manage toxicities associated with ADCs and bispecific antibodies commonly used for MM in order to maintain patient quality of life and time on treatment.
• Recall available data with novel ADC- and bispecific antibody-based strategies currently under investigation for MM, and as applicable, discuss clinical trial participation with eligible patients.

CE Credit
CME credit information will be provided to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. 

FACULTY
Dr Cohen — Advisory Committees: Genentech, a member of the Roche Group, GSK, Ichnos Glenmark Innovation Inc, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Novartis; Consulting Agreements: AbbVie Inc, Arcellx, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Caribou Biosciences Inc, Genentech, a member of the Roche Group, GSK, Ichnos Glenmark Innovation Inc, Janssen Biotech Inc, Kite, A Gilead Company, Legend Biotech, Moderna, Pfizer Inc, Prothena, Regeneron Pharmaceuticals Inc, Sanofi; Contracted Research: Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc; Data and Safety Monitoring Boards/Committees: GSK, Janssen Biotech Inc, Kite, A Gilead Company. Prof Dimopoulos — Advisory Committees and Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, BeOne, Bristol Myers Squibb, GSK, Janssen Biotech Inc, Menarini Group, Regeneron Pharmaceuticals Inc, Sanofi, Swixx Biopharma, Takeda Pharmaceutical Company Limited. Dr Trudel — Advisory Committees: AstraZeneca Pharmaceuticals LP, GSK, Janssen Biotech Inc, Kite, A Gilead Company, Opna Bio, Pfizer Inc, Sanofi; Consulting Agreements: GSK; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, K36 Therapeutics, Pfizer Inc, Roche Laboratories Inc.

MODERATOR
Dr Callander has no relevant financial relationships to disclose. 

Research To Practice CME Planning Committee Members, Staff and Reviewers
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from Genentech, a member of the Roche Group, and GSK.

Sheraton New Orleans Hotel
500 Canal Street
New Orleans, LA 70130
Hotel Phone: (504) 525-2500

Meeting Room
Napoleon Ballroom C/D — Third floor

Directions
The Sheraton New Orleans Hotel is located 0.9 miles (15-minute walk) from the New Orleans Ernest N Morial Convention Center, where the 2026 ASH Annual Meeting is taking place.

Program slides will be made available prior to the start of the session.

Registration to attend virtually is open to all professionals.

Please click the link to register for this live event directly on Zoom. Once you register, Zoom will send a confirmation email with your individual link to access the event. Please keep that confirmation email handy. If you do not receive it, contact our support team at meetings@researchtopractice.com.

To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.